This trial is active, not recruiting.

Conditions breast cancer, colorectal cancer, lung cancer, melanoma (skin), pancreatic cancer
Sponsor ICORG- All Ireland Cooperative Oncology Research Group
Start date August 2008
End date December 2015
Trial size 300 participants
Trial identifier NCT00974610, 07-12 ICORG, EU-20949, ICORG-07-12


RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in peptides and proteins and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from patients with malignant melanoma, metastatic breast cancer, advanced lung cancer, pancreatic cancer, or colorectal cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective

Primary Outcomes

Detection of peptide and protein markers in serum
time frame: Ongoing

Secondary Outcomes

Identification of the protein/peptide involved
time frame: Ongoing

Eligibility Criteria

Male or female participants of any age.

DISEASE CHARACTERISTICS: - Diagnosis of 1 of the following advanced metastatic malignancies: - Malignant melanoma - Lung cancer - Breast cancer - Pancreatic carcinoma - Colorectal cancer - Advanced and/or metastatic disease - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Menopausal status not specified PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Collaborative Project on Potential Serum Markers for Malignant Melanoma, Metastatic Breast, Advanced Lung Pancreatic Carcinoma and Colorectal Cancer
Principal investigator Martin Clynes
Description OBJECTIVES: Primary - To assess which potential peptide and protein markers produced by human melanoma, lung, breast, pancreatic, and colorectal cell lines may be detectable in serum of patients from these five disease groups. Secondary - To conduct further extensive investigation with respect to identification of the protein/peptide involved, determination of specificity for each cancer, and development of more sensitive assays to look for such markers in a wider population of patients, including those undergoing therapy. OUTLINE: This is a multicenter study. Blood samples are collected before surgical intervention or treatment to assess peptide and protein markers.
Trial information was received from ClinicalTrials.gov and was last updated in February 2016.
Information provided to ClinicalTrials.gov by ICORG- All Ireland Cooperative Oncology Research Group.